Also known as: Camzyos
Mavacamten is a first-in-class cardiac myosin inhibitor marketed as Camzyos for symptomatic obstructive hypertrophic cardiomyopathy in adults. It improves symptoms and functional capacity in NYHA class II-III disease. The FDA first approved Camzyos on April 28, 2022.
Bristol Myers Squibb, Sanofi, and Pfizer have filed new patent infringement suits over drugs including Camzyos, Lantus, and abrocitinib, while the Federal Circuit denied Sarepta's rehearing bid in a Regenxbio DNA patent case.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07557498 |
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US |
RECRUITING | |
| NCT07541833 |
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM) |
RECRUITING | |
| NCT07529938 |
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy |
COMPLETED | |
| NCT07383025 |
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan |
RECRUITING | |
| NCT07361289 |
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China |
RECRUITING | |
| NCT07168655 |
Mavacamten in Obstructive Hypertrophic Cardiomyopathy |
COMPLETED | |
| NCT07107373 |
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US |
ACTIVE_NOT_RECRUITING | |
| NCT07103655 |
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction |
NOT_YET_RECRUITING | PHASE4 |
| NCT07004972 |
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER) |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06947590 |
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy |
ACTIVE_NOT_RECRUITING | NA |
